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Three unrelated sequence type 131 (ST131), ST58, and ST83 Escherichia coli isolates with low-level resistance to imipenem and
resistance to ertapenemwere recovered in a Spanish hospital from July to October 2012. They were positive for blaOXA-48 carried
by an IncL/M conjugative plasmid, which may have been acquired from Klebsiella pneumoniae.
Resistance to carbapenem antibiotics in Gram-negative bacte-ria has become an increasingly important problemworldwide
over the last 2 decades (1). The most relevant mechanism for this
resistance is the production of carbapenemases, with the respon-
sible genes often carried by plasmids which contribute to their
spread by horizontal gene transfer (2). OXA-48 is a class D -lac-
tamasewhich confers resistance to penicillins andweak, but none-
theless significant, resistance to carbapenems but not to extended-
spectrum cephalosporins (3). This enzyme was first identified in
2004 in Turkey and since then has been reported in many other
countries, mainly those of the Middle East, North Africa, and Eu-
rope, but also in the United States (4–6). OXA-48 is most often
detected inKlebsiella pneumoniae, although other members of the
Enterobacteriaceae family, including Escherichia coli, also produce
it (3). In K. pneumoniae, the blaOXA-48 gene has been located in a
conjugative plasmid of about 60 kb assigned to the IncL/M group
(7). Here, we report the characterization of three E. coliOXA-48-
producing isolates, each obtained from a different patient at a
Spanish hospital (Hospital Universitario Central de Asturias
[HUCA]) over a 3-month period (Table 1). These are the first
OXA-48-producing E. coli isolates detected in our region, and
only one was previously reported in Spain (8). The three patients
underwent surgery, were hospitalized for long periods, were coin-
fected with other bacteria, and received prolonged treatment with
numerous antimicrobials.
The first E. coli isolate (Ec-HUCA 1)was recovered in July 2012
from a colostomy specimen from a 46-year-old female (patient 1)
with postsurgical septic shock. The colostomy specimen was also
positive for K. pneumoniae (isolate Kp-HUCA 4, which was addi-
tionally detected in blood cultures for the same patient and par-
tially characterized in this study) and Morganella morganii. The
second isolate (Ec-HUCA 2) was recovered in October 2012 from
a surgical wound in a 57-year-old male (patient 2) with intestinal
obstruction. After empirical treatment with meropenem, the iso-
latewas detected in thewounddrainage, aswasEnterococcus faeca-
lis. The third isolate (Ec-HUCA 3) was found in a urine sample
from a 68-year-old male (patient 3) with several complications
after septic shock caused by multidrug-resistant Pseudomonas
aeruginosa secondary to a surgical wound infection (Table 1).
Antimicrobial susceptibility tests were performed by disk dif-
fusion assays (Becton Dickinson, Sparks, MD, USA). The Mi-
croscan system (Neg Combo Panel Type 53; Siemens Healthcare
Diagnostics, Deerfield, IL, USA) was applied for the identification
of bacterial isolates and the determination of MICs. The Etest
(bioMérieux, Marcy-l’Étoile, France) was used to determine the
MIC for tigecycline and to confirm the MIC for ertapenem. The
results of the disk diffusion assays (not shown) and the MICs
(Table 2) were interpreted according to CLSI breakpoints that
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TABLE 1 Characteristics of patients and clinical samples positive for E. coli or for E. coli and K. pneumoniae isolates carrying the blaOXA-48 gene and
recovered in a Spanish hospital
Patient no.
(sexa/age
[yr]) Hospital unit Disease/outcome Sample origin Isolate(s)b
Date of
isolation
(day/mo/yr) Final therapy
1 (F/46) General surgery Surgical wound
infection/discharged
Colostomy Ec-HUCA 1, Kp-HUCA 4
(Morganella morganii)
16/7/2012 Ciprofloxacin
2 (M/57) ICUc Surgical wound
infection/discharged
Wound exudate Ec-HUCA 2 (Enterococcus
faecalis)
15/10/2012 Ciprofloxacin, cefoxitin,
vancomycin
3 (M/68) Reanimation Septic shockd/
discharged
Urine Ec-HUCA 3 26/10/2012 Colistin, meropenem,
amikacin
a F, female; M, male.
b Ec, Escherichia coli; Kp, Klebsiella pneumoniae; HUCA, Hospital Universitario Central de Asturias.
c ICU, intensive care unit.
d Septic shock was caused by Pseudomonas aeruginosa, which was not recovered from urine.
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were updated in January 2013 (9). As shown in Table 2, the resis-
tance pattern was different for each of the three E. coli isolates.
Note that each isolate showed intermediate susceptibility to imi-
penem (MICs of 2mg/liter) and resistance to ertapenem (MICs of
2 mg/liter), and they were positive for the modified Hodge test
recommended for the detection of carbapenemases (9).Ec-HUCA
2 was also resistant to third-generation cephalosporins. The K.
pneumoniae isolate recovered from patient 1 was resistant to
third-generation cephalosporins and ertapenem but susceptible
to imipenem. Apart from resistance to -lactam antibiotics, resis-
tance to nalidixic acid, ciprofloxacin, tobramycin, and/or tri-
methoprim-sulfamethoxazole was detected in some of the isolates
(Table 2).
The genes responsible for resistance to carbapenems and ex-
tended-spectrum cephalosporins were identified by PCR amplifi-
cation (10, 11) followed by sequencing. The presence of blaOXA-48
was demonstrated in the threeE. coli isolates andKp-HUCA4, and
blaCTX-M-15 was detected in Ec-HUCA 2 and Kp-HUCA 4. To es-
tablish the location of these genes, plasmid DNA extracted from
each isolate (12) was hybridized with probes specific for the two
genes amplified from Kp-HUCA 4 and labeled as previously re-
ported (13). The same gel was also hybridized with phage  DNA
(Fermentas GmbH, Madrid, Spain), included as a control. The 
probe was generated by random-primed DNA labeling with
digoxigenin-dUTP using the DIG DNA labeling kit (Roche Ap-
plied Sciences). As shown in Fig. 1a, each isolate displayed a dis-
tinct profile, including a common plasmid of ca. 60 kb accompa-
nied by one or more plasmids of various sizes. The ca. 60-kb
plasmid hybridized with the blaOXA-48 probe in the four isolates
(Fig. 1b), while the blaCTX-M-15mapped on plasmids slightly larger
or slightly smaller than 150 kb in Kp-HUCA 4 and Ec-HUCA 2,
respectively (Fig. 1c).
To investigate the self-transfer ability of the blaOXA-48 plasmids,
conjugation experiments were performed using each of the four
isolates as donors and a rifampin-resistant derivative of E. coli J53
as the recipient. Transconjugants were selected on eosin methyl-
ene blue (EMB) agar (Oxoid,Madrid, Spain) containing rifampin
(100 mg/liter) plus ertapenem (0.5 mg/liter). At least four inde-
pendent transconjugants were tested per conjugation with regard
to plasmid content and antimicrobial susceptibility (see Table 2
for representative examples). As expected, each transconjugant
carried the ca. 60-kb plasmid, either alone or together with other
plasmid(s), and each was PCR positive for the blaOXA-48 gene.
These self-transferable blaOXA-48 plasmids were assigned to in-
compatibility group IncL/M by PCR amplification using
transconjugants carrying only this plasmid as the source of the
template DNA and primers targeting the repA, traU, and parA
genes specific for this group (7). Three out of four transconjugants
tested from crosses involving Ec-HUCA 2 harbored the blaOXA-48
plasmid together with the larger blaCTX-M-15 plasmid, and they
were resistant to cefotaxime and other extended-spectrum ceph-
alosporins (Table 2). In contrast, all transconjugants analyzed
from matings involving Kp-HUCA 4 (up to 20) were positive for
the blaOXA-48 gene and plasmid only and showed a resistance pat-
tern consistent with this (Table 2).
Multilocus sequence typing (MLST) (see mlst.warwick.ac.uk/
mlst/dbs/Ecoli/) assigned Ec-HUCA 1, Ec-HUCA 2, and Ec-
HUCA3 to ST131, ST58, and ST83, respectively (Table 2). Pulsed-
field gel electrophoresis (PFGE) performed with XbaI (14)
revealed a different profile for each of the three E. coli isolates, and
the XbaI profile of Kp-HUCA 4 was also different (Fig. 2). Note
that the cluster of E. coli isolates carrying the blaOXA-48 gene was
detected in our hospital during the national outbreak of K. pneu-
moniae producing the OXA-48 carbapenemase (4, 8). As the re-
FIG 1 Plasmid profiles of Klebsiella pneumoniae (Kp) and Escherichia coli (Ec)
isolates producing OXA-48 carbapenemase (a) and hybridization with
blaOXA-48 (b) and blaCTX-M-15 (c) probes. Lanes , phage DNA digested with
PstI, used as reference for the hybridization experiments (the sizes of some of
the linear fragments are shown in parentheses); lanes i and ii, plasmids ob-
tained from E. coli V517 (NCTC 50192) and plasmid RP4 used as molecular
size standards for undigested DNA; lanes 1,Kp-HUCA 4; lanes 2, Ec-HUCA 1;
lanes 3, Ec-HUCA 2; lanes 4, Ec-HUCA 3.
FIG2 XbaI pulsed-field electrophoresis profiles ofKlebsiella pneumoniae (Kp)
and Escherichia coli (Ec) isolates producing OXA-48 carbapenemase. Lane C,
XbaI-digested DNA of Salmonella enterica serovar Braenderup H9812 used as
size standard; lane 1,Kp-HUCA4; lane 2,Ec-HUCA1; lane 3,Ec-HUCA2; lane
4, Ec-HUCA 3.
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sponsible gene appeared to be carried by the same conjugative
IncL/M plasmid in the two species, it may have been transferred
from K. pneumoniae into E. coli isolates which had been circulat-
ing at the time in the same hospital. Such a transfer may have
independently occurredmore than once, as theE. coli isolateswere
not clonally related according to their STs. The presence of
blaOXA-48 in Ec-HUCA 1 (ST131) is particularly worrisome, con-
sidering the ability of the pandemic ST131 clone to acquire genes
encoding extended-spectrum -lactamases, especially blaCTX-M
(15). In Spain, the only reportedOXA-48-producing E. coli isolate
was also ST131 (8). Note that the detection of carbapenem re-
sistance was difficult, because the three E. coli isolates showed
intermediate resistance to imipenem, and that treatment of the
patients was complicated by additional resistances accompanying
OXA-48 production in two out of the three isolates and by coin-
fection of the patients with other bacteria. Altogether, these facts
highlight the risk of high antimicrobial pressure, in conjunction
with long-termhospitalization, for the emergence of new resistant
bacteria. Nevertheless, after the therapy indicated in Table 1, fur-
ther cultures tested negative for OXA-48-producing Enterobacte-
riaceae, and the three patients were eventually discharged from the
hospital.
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